Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Belgium ,Cedric Ververken ,Paolo Vicini ,Desmond James , ,Chief Development Officer ,Confo Therapeutic ,Vrije Universiteit Brussel ,Confo Therapeutics ,Business Wire ,Business ,Health ,Clinical Trials ,Opioids ,Europe ,